Novartis AG has temporarily suspended the production of two of its radioligand drugs at two sites on either side of the Atlantic due to the emergence of potential manufacturing quality issues.
Novartis Radioligand Business Suffers Manufacturing Blow
Just Months After Pluvicto Approval
The Swiss major has hit pause on two manufacturing sites for its radioligands, Pluvicto and Lutathera, mere months after the former’s approval due to emerging quality concerns.
More from Manufacturing
• By
Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.
• By
Sector-specific tariffs, including on pharmaceuticals, could be announced as early as this week.
• By
The German firm’s chairman, Hubertus von Baumbach, is adopting a ‘wait-and-see’ approach to the threat of pharma tariffs.
• By
Trump announced a 26% reciprocal tariff on India but a country-agnostic exemption of pharmaceuticals implies that the interests of Indian firms and the US consumer are protected for now. What is Indian pharma’s business exposure and what is domestic industry saying?
More from Business
• By
There were six biopharma initial public offerings on Western stock exchanges, including five in the US, during the first quarter, but plunging stock values could halt further IPOs.
• By
Sector-specific tariffs, including on pharmaceuticals, could be announced as early as this week.
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.